Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-55659
Bioorg Med Chem 2019 Mar 01;275:700-707. doi: 10.1016/j.bmc.2019.01.013.
Show Gene links Show Anatomy links

Di- and heptavalent nicotinic analogues to interfere with α7 nicotinic acetylcholine receptors.

Brissonnet Y , Araoz R , Sousa R , Percevault L , Brument S , Deniaud D , Servent D , Le Questel JY , Lebreton J , Gouin SG .


???displayArticle.abstract???
In the field of nicotinic acetylcholine receptors (nAChRs), recognized as important therapeutic targets, much effort has been dedicated to the development of nicotinic analogues to agonize or antagonize distinct homo- and heteropentamers nAChR subtypes, selectively. In this work we developed di- and heptavalent nicotinic derivatives based on ethylene glycol (EG) and cyclodextrin cores, respectively. The compounds showed a concentration dependent inhibition of acetylcholine-induced currents on α7 nAChR expressed by Xenopus oocytes. Interesting features were observed with the divalent nicotinic derivatives, acting as antagonists with varied inhibitory concentrations (IC50) in function of the spacer arm length. The best divalent compounds showed a 16-fold lowered IC50 compared to the monovalent reference (12 vs 195 µM). Docking investigations provide guidelines to rationalize these experimental findings.

???displayArticle.pubmedLink??? 30692022
???displayArticle.link??? Bioorg Med Chem